This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cumberland Pharmaceuticals (CPIX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed the most recent trading day at $6.19, moving -0.16% from the previous trading session.
The Zacks Analyst Blog Highlights: Flexible Solutions International, Qiwi, Cumberland Pharmaceuticals, CECO Environmental and Entravision Communications
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Flexible Solutions International, Qiwi, Cumberland Pharmaceuticals, CECO Environmental and Entravision Communications
Has Cumberland Pharmaceuticals (CPIX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CPIX) Outperforming Other Medical Stocks This Year?
Nektar (NKTR) in Focus: Stock Moves 8.8% Higher
by Zacks Equity Research
Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
5 Stocks That Survived May's Market Mayhem
by Swarup Gupta
A few stocks had what it takes to survive the chaos unleashed by the U.S.-China trade war.
Cumberland (CPIX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for May 23rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Is Cumberland (CPIX) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Cumberland (CPIX) possesses solid growth attributes, which could help it handily outperform the market.
Cumberland Pharmaceuticals (CPIX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 11.24%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Cumberland Pharmaceuticals (CPIX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed the most recent trading day at $6.25, moving +0.32% from the previous trading session.
Analysts Estimate Cumberland Pharmaceuticals (CPIX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Cards for Cumberland (CPIX) This Earnings Season?
by Zacks Equity Research
Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cumberland Pharmaceuticals (CPIX) closed at $5.35 in the latest trading session, marking a -0.93% move from the prior day.
Cumberland Pharmaceuticals (CPIX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $5.95, marking a -0.32% move from the previous day.
Cumberland Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Cumberland Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
by Zacks Equity Research
Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.
Flexion Starts Phase III Enrollment on Zilretta for Hip OA
by Zacks Equity Research
Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.
Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds
by Zacks Equity Research
Small drugmakers, in general, are having a decent year, despite failures of key pipeline candidates in pivotal studies.
Cumberland Pharmaceuticals (CPIX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 73.68% and -7.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cumberland Pharmaceuticals (CPIX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cumberland (CPIX) delivered earnings and revenue surprises of 112.50% and 2.25%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?